This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
Jefferies Keeps Their Buy Rating on Astellas Pharma (ALPMF)
Jefferies analyst maintained a Buy rating on Astellas Pharma today and set a price target of Yen2,800.00.
Claim 30% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Astellas Pharma has an analyst consensus of Hold, with a price target consensus of Yen2,352.02.
Based on Astellas Pharma’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of Yen571.21 billion and a net profit of Yen100.32 billion. In comparison, last year the company earned a revenue of Yen517.41 billion and had a GAAP net loss of Yen97.66 billion
Read More on ALPMF:
Disclaimer & DisclosureReport an Issue
- Astellas and HOVON Phase 3 AML Trial for Xospata Misses Survival Goal
- Astellas Flags Risks and Uncertainties Around Sustainability Plans and Pipeline
- Why Is Vir Biotechnology Stock Up Today?
- Astellas Settles Myrbetriq Patent Disputes with Lupin and Zydus
- Astellas-Backed Bladder Cancer Trial Nears Key Data Moment After Study Completion
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
